- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT03176147
Iron Metabolism Parameters At First Trimester and preGnancy outcomE (IMAGE)
Clinical and Biological Predictive Factors of Iron Deficiency Anemia in the Third Trimester of Pregnancy
Iron deficiency anemia is the leading cause of anemia during pregnancy, which can still reach 10 to 20% of pregnant women in developed countries, with potentially serious consequences for the child. Systematic iron supplementation remains controversial.
This study aims to identify in the first trimester of pregnancy clinical and biological predictive factors for the occurrence of iron deficiency anemia in the third trimester of pregnancy.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Objectives: The main objective is to determine the prevalence of anemia (Hb ≤ 11 g / dl) in the third trimester of pregnancy (T3) and to identify the predictive factors in the first trimester (T1).
Type of study: Prospective monocentric cohort.
Experimental plan: Pregnant women are included during the ultrasound of T1. Written consent will be sought after delivery of the information notice. Hemoglobin, classical iron balance (ferritin, transferrin saturation coefficient) as well as other original parameters: hepcidin and the soluble transferrin receptor are assayed. Socioeconomic and clinical parameters likely to favor an iron deficiency are sought through validated questionnaires. Nutritional advice, combined with martial supplementation if necessary, is given according to a standardized management protocol resulting from the current international recommendations and validated by an internal committee. The prevalence of iron deficiency anemia is determined at T3 (after 34 SA). The predictive factors for this anemia will be sought according to the data collected in T1.
The 2012 WHO's recommendations are in favour of a systematic supplementation of pregnant women. Epidemiological studies show that the anaemia at the end of pregnancy increases the risk of severe anaemia in the postpartum hospital stay and the frequency of transfusions in the mother is multiplied by 9. The quality of life of the mother seems too altered by the anaemia with increased susceptibility to infections, cognitive and emotional disorders in the postpartum period and a decrease of capacity of work and performance. In the human new-born, the anaemia is associated with a risk of prematurity, low weight birth and especially a certain degree of later psycho-motor delay, or even perinatal mortality. Side effects of iron orally, it's cost, make debatable systematic supplementation as interventional studies have given contradictory results in terms of morbidity and mortality infant. In areas where the anaemia prevalence is very high, a systematic supplementation of pregnant by 60 mg of iron (with folic acid) is beneficial in children on clues of psycho-intellectual development at 12, 18 and 24 months while multiple supplementation in micronutrients (containing 30 mg of iron) is not effective. However, systematic supplementation in countries with high socioeconomic level did debate. An Australian study Interventional, controlled, randomized conducted at 430 women showed no efficacy on the intellectual development of children in 4 years, without changing the quality of life of the mother during pregnancy, the authors observing even an increase of abnormal behaviors of the children of the mothers in the Group supplemented iron. In another study, the rational is highly questionable, a treatment by Iron versus placebo was given to pregnant women not anaemic with a high haemoglobin (an average of 14 g/dl): the women who took iron had high blood pressure at the end of pregnancy more and their children had a lower birth for the term weight.
In a developed country such as the France, one can legitimately wonder about the potentially harmful effects of routine iron supplementation for a population of pregnant women mainly not anaemic. In Great Britain of the recently published recommendations are pronounced against a systematic supplementation of iron in pregnant women. Other European authors advocate focused on the rate of ferritin supplementation. However, we are lacking of studies allowing, from clinical criteria and biological precise, to better target pregnant women who could benefit from supplementation of iron in the first quarter.
Tipo de estudio
Inscripción (Anticipado)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
Auvergne
-
Clermont-Ferrand, Auvergne, Francia, 63003
- CHU de Clermont-Ferrand
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
Descripción
Inclusion Criteria:
- Pregnant women in the first trimester between 11SA and 13 SA + 6 days
- A written agreement is needed
Exclusion Criteria:
- Women who do not know enough about reading and writing French to answer questionnaires
- Women under 15 at inclusion
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Pregnant women
Pregnant women are included during the ultrasound of T1.
Written consent will be sought after delivery of the information notice.
|
The prevalence of iron deficiency anemia is determined at T3 (after 34 SA).
The predictive factors for this anemia will be sought according to the data collected in T1.
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Periodo de tiempo |
|---|---|
|
Hemoglobin value
Periodo de tiempo: in the third trimestry of pregnancy
|
in the third trimestry of pregnancy
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Rate of clinical and biological factors per patient
Periodo de tiempo: at the first trimestry of pregnancy
|
demographics and clinical factors and biological factors (hepcidine, ferritine, RST)
|
at the first trimestry of pregnancy
|
|
Rate of demographics and clinical factors per patient
Periodo de tiempo: at the first trimestry of pregnancy
|
biological factors (hepcidine, ferritine, RST)
|
at the first trimestry of pregnancy
|
|
Rate of biological factors per patient
Periodo de tiempo: at the first trimestry of pregnancy
|
Such as : hepcidine, ferritine, RST
|
at the first trimestry of pregnancy
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Marc RUIVARD, MD, PhD, CHU de Clermont-Ferrand
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Anticipado)
Finalización del estudio (Anticipado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CHU-336
- 2015-A00454-45 (Otro identificador: 2015-A00454-45)
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Iron deficiency anemia
-
Qualia Life SciencesAún no reclutandoDeficiencias de hierroEstados Unidos
-
Ain Shams UniversityTerminadoComplicaciones hematológicas del embarazoEgipto
-
PharmaLinea Ltd.TerminadoDeficiencia de hierro | La anemia por deficiencia de hierroEslovenia
-
Children's Hospital of PhiladelphiaLucky Iron FishTerminadoDeficiencia de hierro | La anemia por deficiencia de hierroRepública Dominicana
-
University of Mary Hardin-BaylorChemiNutraTerminadoDeficiencia de hierroEstados Unidos
-
Syed Hamza MufarrihAmerican Regent, Inc.ReclutamientoInsuficiencia cardiaca | Deficiencia de hierro | Insuficiencia cardíaca con fracción de eyección reducida (HFrEF) | Insuficiencia cardíaca con fracción de eyección conservada (HFPEF) | Anemia por deficiencia de hierro (IDA)Estados Unidos
-
Nicoletta C MachinHealth Resources and Services Administration (HRSA)ReclutamientoSangrado | Plaqueta | Planchar | Trastornos hemorrágicosEstados Unidos
-
University of British ColumbiaUniversity of Guelph; NCHADS - Ministry of Health of CambodiaTerminadoAnemia, deficiencia de hierro | Anemia | HemoglobinopatíasCamboya
-
University of Maryland, BaltimoreTerminadoDeficiencia de hierro no anémicaEstados Unidos
-
Emory UniversityInternational Food Policy Research InstituteTerminado